RJFSA
ABCL icon

Raymond James Financial Services Advisors’s AbCellera Biologics ABCL Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$27.4K Sell
10,552
-1,183
-10% -$3.28K ﹤0.01% 3385
2024
Q2 		$34.7K Buy
11,735
+300
+3% +$1.14K ﹤0.01% 3322
2024
Q1 		$51.8K Buy
11,435
+500
+5% +$2.55K ﹤0.01% 3293
2023
Q4 		$62.4K Buy
+10,935
New +$50.7K ﹤0.01% 3179

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raymond James Financial Services Advisors's ABCL Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its AbCellera Biologics (ABCL) stake by 10% in Q3 2024, selling an estimated $3.28K and leaving 10,552 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3385.

Raymond James Financial Services Advisors first reported a position in ABCL in Q4 2023 and has held it in 4 quarters since. The position peaked at $62.4K in Q4 2023. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Raymond James Financial Services Advisors held 10,552 shares of AbCellera Biologics worth $27.4K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 1,183 AbCellera Biologics shares in Q3 2024, an estimated $3.28K.
  • AbCellera Biologics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3385 holding.
  • Raymond James Financial Services Advisors first reported a position in AbCellera Biologics in Q4 2023 and has held it in 4 quarters since.
  • Raymond James Financial Services Advisors's AbCellera Biologics position peaked at $62.4K in Q4 2023.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.